跳至主要内容
临床试验/NCT04942483
NCT04942483已完成不适用

Biomarkers in Preschool Children With Wheeze to TArget Therapy wIth inhaLed cORticosteroids (TAILOR): a Feasibility Study".

Imperial College London1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2021年11月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
118
试验地点
1
主要终点
Wheeze Attacks

研究概览

简要总结

Wheezing is common in preschool children and affects quality of life. Although asthma treatments such as inhaled steroids (ICS), which reduce swelling (inflammation) in the airways are used in this age group, they are often ineffective. That is because only some preschool children have the type of inflammation (known as Type 2 inflammation) that responds to ICS, thus many children are being unnecessarily exposed to side effects. It is difficult diagnosing Type 2 inflammation through history and examination, thus other indicators are needed to ensure ICS are only given to children who will benefit. These indicators are commonly known as biomarkers, and we are trying to find out if they are useful. We want to measure three biomarkers, without changing children's treatment. The first is blood eosinophils. which can be measured using a finger prick sample (like the blood drop used for measuring sugar levels in diabetic children). The second is to determine if allergic sensitization is present to allergens that are breathed in; these will be house dust mite, grass pollen, tree pollen, cat and dog hair. The final biomarker is a molecule that is produced in the airways of preschool children with Type 2 inflammation, called nitric oxide (NO). This is easily obtained, by having children breathe through a mask and collecting their breath in a bag, measuring NO later on. The children will be followed up with monthly electronic questionnaires and 3-monthly visits (virtual or face-to-face) for a year to evaluate whether these markers individually or in combination relate to subsequent wheezing outcomes, and how acceptable the measurements are to families using a questionnaire and focus group approach. The results will form the basis of the design of a national trial of biomarker-driven therapy in such children.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
1 Year 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients aged one to five years old presenting to primary care or emergency department or urgent care centre or identified from primary care records and have been diagnosed with wheezing by their GP or paediatrician who has decided to prescribe any bronchodilator, ICS or montelukast on clinical grounds
  • Parents/Carers able to understand and familiarize themselves with the study and are willing to provide informed consent

排除标准

  • Inability to understand and cooperate with study procedures
  • Significant co-morbidity (respiratory or otherwise), for example cystic fibrosis (excluding atopic disorders such as eczema, allergic rhinitis and food allergy)
  • Withholding or withdrawal of informed consent
  • Severe procedural anxiety (needle phobia)
  • Child is already enrolled in another study involving investigational medicinal product (CTIMP)
  • History of anaphylaxis or near-fatal asthma that resulted in intubation / assisted ventilation.

结局指标

主要结局

Wheeze Attacks

时间窗: 1-year follow-up

Defined as requiring an unscheduled healthcare visit to the ED or GP.

次要结局

  • Days Out of Nursery(1 year follow-up period)
  • Parents Days Out of Work(1 year follow-up period)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验